Haohai Biological reports revenue, profit decline in Q3 2025

Shanghai Haohai Biological Technology Co. Ltd. reported a significant decrease in key financial metrics for the third quarter and first nine months of 2025. Revenue for the third quarter stood at RMB594,683,000.09, an 11.29% year-on-year decline, while total profit fell by 11.36% to RMB109,873,258.09. Net profit attributable to shareholders also decreased by 11.39% to RMB93,582,140.40. For the nine-month period, total revenue was RMB1,899,085,771.17, down 8.47%, and net profit attributable to shareholders was RMB304,647,394.30, a 10.63% reduction compared to the same period last year.

The company's net profit after deducting non-recurring profit or loss attributable to shareholders saw a sharper decline of 44.54% for the quarter, amounting to RMB50,507,259.89. This was attributed to factors such as insufficient domestic consumer demand, price competition, and tax rate adjustments. Total R&D expenses for the quarter decreased by 19.19% to RMB50,698,539.50. Basic and diluted earnings per share for the quarter were RMB0.40, an 11.11% decrease.

As of September 30, 2025, total assets were RMB7,118,072,329.69, a marginal decrease of 0.05% from the end of last year. Equity attributable to shareholders of the company, however, saw a slight increase of 0.73% to RMB5,615,759,432.49.